ResearchPoint Names Former inVentiv Clinical Solutions VP, Stacey Arrambide, to Lead Data Management and Biostatistics

Deep Experience in Biostatistics Further Expands ResearchPoint’s Data Operations Division

AUSTIN, Texas--(BUSINESS WIRE)-- ResearchPoint, a leading global CRO, announced that Stacey Arrambide has joined the company to lead the biostatistics and data management division. Arrambide, with over 12 years of clinical development experience, oversees ResearchPoint’s biostatistics and data management operations. Mr. Arrambide has experience in all aspects of drug and device clinical development including study design, summaries of safety and efficacy, data management and data validation activities. He has worked extensively with the SAS® system, various EDC systems, and has experience representing clients at FDA meetings.

Arrambide is “excited to be getting back to a mid-size CRO to work more closely with the clients and see direct benefits to the patients. At the end of the day, our work is about improving the lives of the patients.”

Prior to ResearchPoint, Arrambide was vice president of data management with inVentiv Clinical Solutions, where he led multiple offices throughout the U.S. He began his career with Synergos, a full-service CRO, headquartered in Houston, Texas, working his way through the ranks from statistician to vice president of statistics and data management, prior to the acquisition from inVentiv in 2006. Throughout his career, Stacey has worked with numerous small and large medical device and pharmaceutical companies.

Arrambide is most proud of a particular work accomplishment, one that required extensive involvement on a deep brain stimulator for Parkinson’s. While attending meetings with the FDA, he visited with some of the patients of this device, witnessing the vast improvements in quality of life. The product was approved and he said, “To have been a part of this effort was absolutely amazing.”

VP Operations, ResearchPoint, Becky Causey, commented, “Stacey's unique blend of hands-on leadership experience in both data management and biostatistics is perfectly suited for the ResearchPoint customer-focused model. Our typical client is looking for a different level of service provider, one that can seamlessly complement their own team by offering not only exceptional quality, but also strategic guidance based upon a broad understanding of the challenges we often face. Stacey's cross-functional background makes him the ideal complement to our existing leadership team.”

Matt Walker, EVP Business Development and Marketing, ResearchPoint, believes Arrambide is an excellent strategic addition to the team. “He adds significantly to our ability to better serve our clients, both because of his overall leadership for our data operations, and the core role he plays in further strengthening ResearchPoint’s statistics team. One of the things we are particularly excited about is leveraging his depth of experience with device trials.”

Arrambide holds a Bachelor’s degree in Mathematics and Master’s degree in Statistics from Sam Houston State University. He has contributed to and published numerous articles in peer-reviewed journals.

ResearchPoint is a full-service contract research organization (CRO) providing drug and device development services worldwide. With expertise spanning all major therapeutic areas, ResearchPoint delivers a unique blend of an experienced team, combined with the creativity, responsiveness, and customer focus of a highly nimble organization. With ResearchPoint, your clinical trial journey is always managed by our A-team, resulting in the ideal outsourcing experience from study start-up through delivery of the final report. Expect the destination. Enjoy the journey. For more information, visit www.researchpoint.com



CONTACT:

ResearchPoint
Heather Attridge, 512-343-1092
[email protected]

KEYWORDS:   United States  North America  Texas

INDUSTRY KEYWORDS:   Stem Cells  Technology  Data Management  Practice Management  Health  Biotechnology  Cardiology  Clinical Trials  Genetics  Infectious Diseases  Medical Devices  Mental Health  Oncology  Optical  Pharmaceutical  Research  Diabetes  FDA  Science

MEDIA:

Logo
 Logo

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.